T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines

Journal of Immunotherapy

Volumn 21, Issue 5, 1998, Pages 352-362

  Nishimura, Michael I ^a   Custer, Mary C ^a   Schwarz, Susan L ^a   Parker, Linda L ^a   Mixon, Arnold ^a   Clay, Timothy M ^a   Yannelli, John R ^a,b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

CD4+ T cells; Melanoma antigen; T cell receptor

Indexed keywords

CD4 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; CELL INFILTRATION; GENE REARRANGEMENT; HELPER CELL; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR BINDING; SUPPRESSOR CELL; T LYMPHOCYTE;

EID: 0031683169     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199809000-00003     Document Type: Article

References (51)

1. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318.
2. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991; 83:932.
3. Arienti F, Belli F, Rivoltini L, et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 1993;36:315.
4. + T cells in cancer immunotherapy. Curr Opin Immunol 1994;6:741.
5. Arancia G, Malorni W, Donelli G. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells. Ann 1st Super Sanita 1990; 26:369.
6. Plate JM, Lukaszewska TL, Bustamante G, Hayes RL. Cytokines involved in the generation of cytolytic effector T lymphocytes. Ann NY Acad Sci 1988;532:149.
7. Kaye J, Kersh G, Engel I, Hedrick SM. Structure and specificity of the T cell antigen receptor. Semin Immunol 1991; 3:269.
8. Bjorkman PJ, Saper MA, Samroaui B, Bennett WS, Stominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329: 512.
9. Stern LJ, Brown JH, Jardetsky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215.
10. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334:395.
11. Kaye J, Vasque NJ, Hedrick SM. Involvement of the same region of the T cell antigen receptor in thymic selection and foreign peptide recognition. J Immunol 1992; 148:3342.
12. Sorger SB, Paterson Y, Fink PJ, Hedrick SM. T cell receptor junctional regions and the MHC molecule affect the recognition of antigenic peptides by T cell clones. J Immunol 1990; 144:1127.
13. Nishimura MI, Kawakami Y, Charmley P, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes: analysis of melanoma-specific long-term lines. J Immunother 1994; 16:85.
14. Cole DJ, Weil DP, Shamamian P, et al. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res 1994;54:5265.
15. Shilyansky J, Nishimura MI, Yannelli JR, et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci USA 1994;91: 2829.
16. Sensi M, Parmiani G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 1995:16:588.
17. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas, J Immunol 1989; 142:3714.
18. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58:69.
19. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458.
20. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991; 146:3674.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156.
22. Loh EY, Elliott JF, Cwirla S, Lanier LL, Davis MM. Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain. Science 1989;243:217.
23. Roman-Roman S, Ferradini L, Azacar J, Genevee C, Hercend T, Triebel F. Studies on the human T cell receptor alpha/beta variable region genes. I. Identification of 7 additional V alpha subfamilies and 14 J alpha gene segments. Eur J Immunol 1991; 21:927.
24. Ferradini L, Roman-Roman S, Azocar J, Michalaki H, Triebel F, Hercend T. Studies on the human T cell receptor alpha/beta variable region genes. II. Identification of four additional V beta subfamilies. Eur J Immunol 1991; 21:935.
25. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1997;74:5463.
26. Deveraux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1984; 123:87-95.
27. Kawakami Y, Robbins PF, Wang PF, Rosenberg SA. Identification of tumor-regression antigens in melanoma. In: DeVita VT, Heilman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott, 1996: 3-21.
28. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992; 148:638.
29. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992:12:1.
30. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. Blood 1993;82:1204.
31. + lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 1995;40:1.
32. + melanoma. Int Immunol 1993;5:1501.
33. + T lymphocytes. J Interferon Cytokine Res 1995; 15:739.
34. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91: 9561.
35. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN. Induction of pigmentation in mouse fibroblasts by expression of human tryosine cDNA. J Exp Med 1989; 169:2029.
36. + T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772.
37. Anichini A, Mortarini R, Maccalli C, et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996:156:208.
38. Kirkin AF, Thor Straten P, Zeuthen J. Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother 1996;42:203.
39. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072.
40. Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 1995;25:1638.
41. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995:92:11993.
42. Van Elsas A, Nijman HW, Van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 1995;61: 389.
43. Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996;23:118.
44. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigen peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976.
45. Wolfel T, Hauer M, Schneider J, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281.
46. Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183:1185.
47. Maeurer MJ, Martin DM, Storkus WJ, Lotze MT. TCR usage in CTLs recognizing melanoma/melanocyte antigen. Immunol Today 1995; 16:603.
48. Dufour E, Carcelain G, Caudin C, Flament C, Avril MF, Faure F. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol 1997; 158:3787.
49. Koop BF, Rowen L, Wang K, et al. The human T-cell receptor TCRAC/TCRDC (C alpha/C delta) region: organization, sequence, and evolution of 97.6 kb of DNA. Genomic 1994; 19:478.
50. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455.
51. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996; 272:1755.